Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase II for Cytopenia. According to GlobalData, Phase II drugs for Cytopenia have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Iodine i 131 apamistamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iodine i 131 apamistamab overview
Iomab-B, a radioimmunoconjugate (BC8-I-131 construct) is under development for the treatment of relapsed and refractory follicular lymphoma, chronic lymphocytic leukemia, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, relapsed and refractory B-cell acute lymphoblastic leukemia and chronic myeloid leukemia (CML), acute myelocytic leukemia (AML), HIV-related lymphoma, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative disorders, relapsed and/or refractory elderly acute myeloid leukemia,chronic myelomonocytic leukaemia, refractory anemia with excess blasts, cytopenia, multiple myeloma and refractory anemia with ringed sideroblasts and for prevention of lymphodepletion during CAR-T therapy. The drug candidate is also under development for bone marrow conditioning before a hematopoietic stem cell transplant (HSCT), in relapsed/refractory elderly AML patients. It is administered intravenously. Iomab-B consists of the monoclonal antibody apamistamab and the beta emitting radioisotope I131 (I-131). It acts by targeting CD45 and is developed by using Alpha Particle Immunotherapy (APIT) platform. It was also under development for Hodgkin lymphoma, relapsed/refractory B-non-Hodgkin lymphoma (B-NHL), T-non-Hodgkin lymphoma(T-NHL) and mantle cell lymphoma,
Actinium Pharmaceuticals overview
Actinium Pharmaceuticals (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company’s pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE Technology Platform. It develops products to treat colon, prostrate and brain cancer. ATNM is headquartered in New York City, New York, the US.
For a complete picture of Iodine i 131 apamistamab’s drug-specific PTSR and LoA scores, buy the report here.